Fulltext

Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study

Rauch, A. ; Nolan, D. ; Martin, A. ; McKinnon, E. ; Almeida, C. ; Mallal, Simon

In: Clinical Infectious Diseases, 2006, vol. 43, no. 1, p. 99-102

Ajouter à la liste personnelle
    Titre
    • Prospective Genetic Screening Decreases the Incidence of Abacavir Hypersensitivity Reactions in the Western Australian HIV Cohort Study
    Auteur
    • Rauch, A.. Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    • Nolan, D.. Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    • Martin, A.. Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    • McKinnon, E.. Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    • Almeida, C.. Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    • Mallal, Simon. Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Clinical Infectious Diseases, 2006, vol. 43, no. 1, p. 99-102. The University of Chicago Press
    Autre version électronique
    Classification
    • Santé
    Identifiant OAI-PMH
    • oai:doc.rero.ch:299971
    Summary
    Abacavir therapy is associated with significant drug hypersensitivity in ∼8% of recipients, with retrospective studies indicating a strong genetic association with the HLA-B*5701 allelle. In this prospective study, involving 260 abacavir-naive individuals (7.7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients